Abstract
The optimal strategy for control of pandemic influenza is early vaccination with influenza vaccine produced from influenza pandemic strains. However, for pandemic control, vaccine improvements are essential and should include quicker ways of manufacturing and testing of vaccine as well as flexibility on the part of licensing bodies. The production of mass doses of monovalent vaccine in a short time can be more realistic if egg independent production technology can be adopted. In this respect production of an influenza vaccine on a stable cell line can solve many of the problems in increased production of influenza vaccine. But the difficulty with influenza vaccines is that the yield of human influenza viruses on tissue culture is much lower than in embryonated eggs. A new high-yield donor is needed for construction of recombinants with a new pandemic strain, which can replicate in a stable cell line with high titre. The live influenza vaccine may be the most appropriate for prophylaxis of influenza pandemic, as the implementation of this vaccine for mass vaccination is simpler than of inactivated influenza vaccine, and this vaccine, after one immunization of unprime persons, induces local mucocosa immunity which plays an important role in the protection against influenza.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Shortridge K. An influenza epicentre? Lancet 1982 (ii): 812.
Interagency Work Group on Influenza (HEW, PHS, CDC). Plan for pandemic influenza. Centers for Diseases Control, 8 May 1978.
Tannock G, Bryce D, Paul J. Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain A/Ann/Arbor/6/70-ca. Vaccine 1985; 3: 333–339.
Rogers G, Paulson J. Receptor determinants of human and animal influenza virus isolates: Differences in recepter specificity at the H3 hemagglutinin based on species of origin. Virology 1983; 127: 361–173.
Wright P, Karzon D. Live attenuated influenza vaccines. Prog Med Virol 1987; 34: 70–77.
Ghendon Y. Vaccination against influenza viruses: Current status. Viral Vaccines. New York: Wiley-Liss, 1990: 159–201.